Many disease states and postoperative complications are the direct result of inflammation and the body’s consequent inability to restore a normal state of function. It is known that regenerative healing occurs in the fetal environment due to the inherent ability of the placental tissues to modulate inflammation. Research has shown that this occurs because the placental tissues, particularly the umbilical cord and amniotic membrane, have innate regenerative properties. More importantly, these properties can be preserved and transplanted to other environments.
With more than 25 years of National Institute of Health funded research efforts, TissueTech™ has developed and commercialized proprietary technology that preserves the innate regenerative properties of the umbilical cord and amniotic membrane. The preservation of these key healing components provides an allograft that promotes the modulation of inflammation to support healing without the formation of scar tissue or adhesions and to minimize the pain that is customarily associated with such inflammation.
TissueTech currently provides cryopreserved amniotic membrane products and is the first company to provide umbilical cord products in the market. The Company’s groundbreaking scientific research in regenerative medicine will support continued development of innovative cellular and tissue-based drug and biologic products. to treat an ever-broadening array of clinical conditions. More than 200,000 TissueTech allografts have been transplanted to date, benefitting thousands of patients.